Document is current
Any future updates will be listed below
-
Authors
Tigelaar, Leonie G.
Prins, Isabel J.
Haveman, Lianne M.
Van der Torre, Patrick
Van der Hoek, Hinke
Merks, Johannes H. M.
Schreuder, Hendrik W. B.
Bekkering, Willem P.
- License Information
-
More Information
Article History
Received: 29 December 2025
Accepted: 17 March 2026
First Online: 11 April 2026
Declarations
:
: This study was performed with the approval of the Clinical Research Committee of the Princess Máxima Center for pediatric oncology. The Medical Ethics Committee Utrecht has confirmed that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study (reference MvdL/avd/21/500354).
: Informed consent was obtained from all patients and/or parents, depending on the age of the patient.
: JM has received consulting fees from Bayer and Merck (each <€5,000, paid to the institution), serves on the Data Safety Monitoring Board for the Pervision trial (EudraCT 2022-002793-91) and holds unpaid leadership positions as Chair of the European Pediatric Soft Tissue Sarcoma Study Group and Vice Chair of the EuroEwing Consortium. The remaining authors have no relevant financial or non-financial interests to disclose.
